NASDAQ
0.64USD
-0.18 (-22.56%)
We have scored 8 news catalysts on Propanc Biopharma, Inc. (PPCB) over the past 12 months. The biggest single-day move next to one of them came Jun 11, 2026, when PPCB closed +80.0%: “Dow Jumps Over 250 Points; US Initial Jobless Claims Rise”. Coverage across the window leans positive (average ticker sentiment +0.50). Most of the impact sits in short squeeze potential and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.4M
P/E
—
EPS
—
Beta
3.33
52W range
0.627-60
Day range
0.63–0.86
Open
0.84
Prev close
0.82
Volume
1M
Avg volume
3.9M
Dividend
0.00
IPO
2012-11-12
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Propanc Biopharma, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for PPCB: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
